|
| Patients (N) | Autoantibodies | Methods | Study design | Authors (reference no.) |
|
| POF |
|
| POF (45) | AOA 47%*
Antioocyte Aab 47%*
AOA or anti-oocyte Aab 69%*
Anti-LH 6.7% (also AOA positive)
AThA 18%*
Antiplacental Aab 22%* | ELISA | CC | Luborsky et al. 1990 [30] |
|
| POF (45) | AOA 24–60%* | ELISA | CC | Wheatcroft et al. 1994 [68] |
|
| POF (48) | Anti-3 beta hydroxysteroid dehydrogenase Aab 21%* | IB, IF, cDNA screening | CC | Arif et al. 1996 [69] |
|
| POF (46) | AOA IgG, IgA or IgM 59%—IgG 74.1%, IgA 33.3%, IgM 29.6%* | ELISA | CC | Fénichel et al. 1997 [29] |
|
(A) POF (14)
(B) IVF poor responders (29)
(C) IVF good responders (14) | FSH blocking IgG:
(A) 21.4%
(B) 6.9%
(C) 85%*
| IgG purification, cell culture exposure | CC | Reznik et al. 1998 [70] |
|
POF (30)
Unexplained infertility (38) | AOA and AThA 60%*
ANA and ACA 16%*
AOA 53%*
AThA 30%* | EIA | CC | Luborsky et al. 1999 [32] |
|
| POS positive for AOA (36) | Anti-FSH (anti-V14D) 94.4%* | ELISA, IB, IF, peptide screening | P | Gobert et al. 2001 [71] |
|
| POF (15) | AOA 66.6%*
Antizona pellucida Aab 53.3%*
TMA 33.3% | IHC | CC | Kelkar et al. 2005 [31] |
|
| IVF patients |
|
| IVF poor responders with male infertility or TFI (26) | AOA 77%*
Anti-FSH 92%*
Anti-LH 65%*
| ELISA | CC | Meyer et al. 1990 [72] |
|
| IVF failure (80) | AOA 12.5%* | IF | CC | Geva et al. 1999 [62] |
|
| IVF failure (17) | 1 out of 6 common Aab IgG 82.3%*:
ACA 58.8%
LA 47.1%
AThA 58.8%
ANA 58.8%
SMA 11.8% | ELISA, IF, PDCA | CC | Putowski et al. 2004 [61] |
|
IVF patients (135):
(A) PCOS, endometriosis, unexplained infertility
(B) TFI or male infertility | (A) and (B) higher titer of anti-FSH IgG, IgA and IgM* (A) 1 out of 7 common Aab IgG 49%*-ANA 2 preparations, SMA, PCA, ACA, B2-GPI or anti-TPO | ELISA, IF | CC | Haller et al. 2007 [73] |
|
| IVF poor responders (16) | Anti-FSH IgA 37.5%*
Anti-FSH IgG 31.3%* | ELISA | CC | Haller et al. 2008 [74] |
|
| TFI with IVF failure (156) | AEA IgA* (antialpha enolase) | IB, MS | CC | Sarapik et al. 2010 [43] |
|
| TFI (21) | Antichlamydial HSP60 antibody titer* | ELISA, IB, IF | CC | Rodgers et al. 2010 [42] |
|
| Non-IVF infertility patients |
|
(A) Unexplained infertility (26)
(B) Unexplained abortion (24) | 2 APA, 5 antihistone or 4 antipolynucleotide IgG, IgA or IgM (A 88% and B 70.8%) | ELISA | P | Gleicher et al. 1989 [66] |
|
Pregnancy complications (69):
(A) Early pregnancy loss
(B) Foetal death
(C) Preeclampsia | AThA 37.7%*:
(A) 37.9%*
(B) 40.9%*
(C) 33.3%* | ELISA, PDCA, RIA | CC | Mecacci et al. 2000 [11] |
Infertility (108):
Menstrual cycle disturbances
Anovulation
Luteal phase deficiency
Unexplained infertility
PCOS
Endometriosis | 1 out of 9 common Aab IgG 40.7%*
ANA 13.9%*
SMA 27.8%*
TMA 1.9%*
PCA 0.6%
B2-GPI 4.4%
ACA 5% | ELISA, IF | CP | Reimand et al. 2001 [25] |
|
Infertility (438):
Endometriosis
TFI
Ovarian dysfunction
Male infertility
Unexplained infertility | Anti-TPO 14%:
18% in female infertility*
29% in endometriosis* | RIA | CC | Poppe and Velkeniers 2002 [60] |
|
(A) Infertility (178)—PCOS, endometriosis
(B) Uncomplicated pregnancy (75) | (A) higher titer of anti-FSH (anti-V14D) IgA*
(B) lower titer of anti-FSH (anti-V14D) IgG, IgM* | ELISA | CC | Haller et al. 2005 [75] |
|
| Infertility-related diseases |
|
| Endometriosis (13) | AOA, AEA, anti-theca cell Aab, anti-granulosa cell Aab titers* | IF, PHA | CC | Mathur et al. 1982 [50] |
|
| Endometriosis (59) | ANA 28.8%, LA 45.5% (inversely related to disease stage)
1 out of 16 antigens IgG 64.5%
1 out of 16 antigens IgM 45.2% | IF, PDCA | P | Gleicher et al. 1987 [21] |
|
| Endometriosis (60) | Anti-α 2HS glycoprotein and antitransferrin titers* | ELISA | CC | Mathur et al. 1999 [49] |
|
| PCOS (34) | AOA IgG, IgA or IgM 44%—IgG 27%, IgA 3%, IgM 27%* | ELISA | CC | Fénichel et al. 1999 [19] |
|
